Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 13 | 2025 | 471 | 5.100 |
Why?
|
| Postpartum Period | 14 | 2025 | 231 | 3.680 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2025 | 768 | 2.430 |
Why?
|
| Delivery, Obstetric | 6 | 2020 | 267 | 2.250 |
Why?
|
| Opioid-Related Disorders | 4 | 2023 | 285 | 2.230 |
Why?
|
| Pain | 7 | 2023 | 457 | 1.730 |
Why?
|
| Cesarean Section | 3 | 2023 | 424 | 1.650 |
Why?
|
| Pregnancy | 27 | 2026 | 7555 | 1.540 |
Why?
|
| Pain Management | 6 | 2025 | 196 | 1.540 |
Why?
|
| Premature Birth | 3 | 2022 | 419 | 1.530 |
Why?
|
| Prenatal Care | 6 | 2023 | 359 | 1.500 |
Why?
|
| Inpatients | 5 | 2024 | 552 | 1.180 |
Why?
|
| Patient Discharge | 5 | 2024 | 512 | 1.010 |
Why?
|
| Pain Measurement | 4 | 2025 | 355 | 0.940 |
Why?
|
| Pregnancy Outcome | 3 | 2020 | 635 | 0.920 |
Why?
|
| Gonorrhea | 1 | 2023 | 40 | 0.790 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 49 | 0.790 |
Why?
|
| Syphilis | 1 | 2023 | 98 | 0.750 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 95 | 0.740 |
Why?
|
| Labor, Obstetric | 1 | 2022 | 102 | 0.720 |
Why?
|
| Histoplasmosis | 3 | 2026 | 55 | 0.700 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2021 | 35 | 0.690 |
Why?
|
| Female | 32 | 2026 | 70695 | 0.670 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 428 | 0.670 |
Why?
|
| Maternal Health Services | 1 | 2021 | 47 | 0.660 |
Why?
|
| Obstetrics | 2 | 2025 | 245 | 0.660 |
Why?
|
| Hypoglycemia | 1 | 2021 | 183 | 0.650 |
Why?
|
| Pregnancy, Triplet | 1 | 2020 | 10 | 0.640 |
Why?
|
| Analgesia, Obstetrical | 1 | 2019 | 9 | 0.640 |
Why?
|
| Analgesia | 1 | 2020 | 43 | 0.620 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 724 | 0.610 |
Why?
|
| Fertilization in Vitro | 1 | 2020 | 161 | 0.580 |
Why?
|
| Postnatal Care | 1 | 2018 | 52 | 0.550 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 180 | 0.540 |
Why?
|
| Retrospective Studies | 13 | 2023 | 17416 | 0.530 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 498 | 0.500 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 305 | 0.480 |
Why?
|
| Vaccination | 1 | 2021 | 1018 | 0.480 |
Why?
|
| Lung Diseases, Fungal | 2 | 2026 | 37 | 0.480 |
Why?
|
| Humans | 32 | 2026 | 132089 | 0.470 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 272 | 0.450 |
Why?
|
| Influenza, Human | 1 | 2021 | 699 | 0.450 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 487 | 0.440 |
Why?
|
| Bariatric Surgery | 1 | 2016 | 139 | 0.430 |
Why?
|
| Prospective Studies | 6 | 2024 | 6572 | 0.400 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 923 | 0.400 |
Why?
|
| Infant, Newborn | 7 | 2023 | 8549 | 0.390 |
Why?
|
| Adult | 13 | 2026 | 31575 | 0.390 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 552 | 0.350 |
Why?
|
| Steroids | 2 | 2022 | 173 | 0.340 |
Why?
|
| HIV Infections | 1 | 2023 | 2038 | 0.340 |
Why?
|
| Illinois | 2 | 2019 | 17 | 0.310 |
Why?
|
| Antifungal Agents | 3 | 2026 | 312 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 339 | 0.290 |
Why?
|
| Gestational Age | 2 | 2022 | 1224 | 0.270 |
Why?
|
| Cohort Studies | 4 | 2020 | 5168 | 0.260 |
Why?
|
| Obesity | 1 | 2016 | 2395 | 0.220 |
Why?
|
| Depression, Postpartum | 1 | 2024 | 54 | 0.210 |
Why?
|
| Young Adult | 4 | 2024 | 9958 | 0.200 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 6 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 215 | 0.190 |
Why?
|
| Histoplasma | 3 | 2026 | 37 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 485 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 106 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2025 | 669 | 0.180 |
Why?
|
| Pregnancy in Diabetics | 1 | 2021 | 17 | 0.170 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 94 | 0.160 |
Why?
|
| Fertilization | 1 | 2020 | 43 | 0.160 |
Why?
|
| Aftercare | 1 | 2021 | 155 | 0.160 |
Why?
|
| Emotions | 1 | 2022 | 367 | 0.150 |
Why?
|
| Maternal Age | 1 | 2020 | 139 | 0.150 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2020 | 76 | 0.150 |
Why?
|
| Diabetes, Gestational | 1 | 2020 | 114 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 257 | 0.150 |
Why?
|
| Mass Screening | 1 | 2023 | 830 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2026 | 496 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 20 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1439 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2026 | 779 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 20560 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3416 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 1900 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1410 | 0.080 |
Why?
|
| United States | 2 | 2023 | 11667 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 6448 | 0.080 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2006 | 33 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2006 | 29 | 0.060 |
Why?
|
| Motor Cortex | 1 | 2006 | 83 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2006 | 236 | 0.050 |
Why?
|
| Acute Disease | 1 | 2026 | 1160 | 0.050 |
Why?
|
| Child | 4 | 2026 | 25786 | 0.050 |
Why?
|
| Risk Factors | 1 | 2016 | 10946 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 233 | 0.040 |
Why?
|
| Anxiety | 1 | 2024 | 994 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3766 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2006 | 15 | 0.020 |
Why?
|
| Propylamines | 1 | 2006 | 8 | 0.020 |
Why?
|
| Methylphenidate | 1 | 2006 | 58 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13061 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2006 | 109 | 0.010 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 128 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 200 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 329 | 0.010 |
Why?
|
| Tourette Syndrome | 1 | 2006 | 158 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1658 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 2697 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 4528 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 13034 | 0.010 |
Why?
|
| Male | 1 | 2006 | 64967 | 0.000 |
Why?
|